However, when the 2 arms were analyzed separately, significant increases were noted in each arm for lean body mass (by about 2.5 kg, ABT-263 molecular weight both P < .04) and 6-minute walk distance (approximately 50 m, both P < .04). No change was noted for physical activity or grip strength. Resting energy expenditure decreased significantly in both groups. Body weight was increased in the group that received megestrol acetate only (from 54.7 ± 10.8 to 57.2 ± 11.8 kg, P = .05). L-carnitine on its own also has been successfully used in 72 patients with advanced pancreatic cancer as part of a prospective, multicenter,

placebo-controlled, randomized, and double-blinded trial.31 Patients received oral L-carnitine at a dose of 4 g or placebo. At study entry, patients reported a mean weight loss of 12.0 ± 2.5 kg. During 12 weeks of treatment, body mass index increased by 3.4% ± 1.4% under L-carnitine and decreased by 1.5% ± 1.4% in controls (P < .05). Likewise, body fat and body BIBW2992 cell line cell mass increased in the L-carnitine group only. The appetite stimulant megestrol acetate also has been successfully used in children. Cuvelier et al32 randomized, in a double-blind fashion, 26 children to receive an oral suspension of megestrol acetate

(7.5 mg/kg/d) or placebo for 90 days. Patients enrolled into the study were younger than 18 years of age and presented with weight loss of 5% or more secondary to cancer and/or cancer treatment. http://www.selleck.co.jp/products/hydroxychloroquine-sulfate.html Children on megestrol acetate experienced an average weight gain of +19.7% compared with a mean weight loss of 1.2% in the placebo group (P = .003). 32 All patients in the megestrol acetate group developed at least one undetectable early morning serum cortisol level during the study; this occurred only in 1 patient on placebo. Severe adrenal suppression was reported in 2 patients on megestrol acetate. Other adverse effects were not different between this and the placebo group. 32 Melatonin has been

shown to improve appetite in animal experiments.33 Del Fabbro et al34 performed a randomized, placebo-controlled trial in patients with advanced lung or gastrointestinal cancer. Unfortunately, the trial was stopped early for futility. This result came as a surprise, because the dosage used in this trial, oral melatonin 20 mg at night, was similar to that used in previous trials and is much higher than that used for conditions such as jet lag (typically 0.5–5.0 mg). A total of 73 patients were enrolled, but it was stopped after 48 subjects had finished the study, because an interim analysis showed that the intervention was unlikely to be of significant benefit. In fact, none of the assessed end points improved: the Edmonton Symptom Assessment Scale (ESAS), the Functional Assessment of Cancer Illness Therapy–Fatigue (FACIT-F), or the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) scores. Also, there was no change in body weight to suggest any benefit of melatonin over placebo (all P > .15).